CERo Therapeutics Holdings (CERO) Stock
CERo Therapeutics Holdings Chart
Company Profile
Price: $0.96
Market Cap: $2.91M
Exchange: NASDAQ
CEO: Mr. Christopher B. Ehrlich M.B.A.
Sector: Healthcare
Industry: Biotechnology
Employees: 8
Headquarters: South San Francisco, CA
Website: CERo Therapeutics Holdings
Business Summary
CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead program in hematologic malignancies targets an Eat Me signal upregulated on B cell and myeloid tumors. The company is based in South San Francisco, California.
CERo Therapeutics Holdings News
CERo Therapeutics Holdings, Inc. Presents Encouraging Preclinical Data Demonstrating CER-1236 May be Targeted to Ovarian Cancer Cells Without Toxicities at 2025 SITC Spring Scientific Cellular Therapy for Solid Tumors Meeting
SOUTH SAN FRANSCISCO, Calif., March 13, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (Nasdaq: CERO) (“CERo” or the “Company”) an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, announces it is presenting encouraging preclinical results of lead compound CER-1236 in ovarian cancer during the 2025 SITC Spring Scientific Cellular Therapy for Solid Tumors in San Diego, March 12-14.
CERo Therapeutics Holdings, Inc. Announces Progress in Initiation of Phase 1 Clinical Trial by Executing an Agreement with Contract Research Organization CellCarta to Manage Translational Assays
Company continues toward the initiation of its Phase 1 Clinical Trial in AML for CER-1236 SOUTH SAN FRANSCISCO, Calif., March 06, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (Nasdaq: CERO) (“CERo” or the “Company”) an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, announces the execution of an agreement with contract research organization (CRO) CellCarta to manage translational assays for the Company's upcoming Phase 1 clinical trial of CER-1236 for Acute Myeloid Leukemia (AML).
CERo Therapeutics Holdings, Inc. to Present Data at the Society for Immunotherapy of Cancer Spring Scientific March 12-14
New poster to highlight preclinical data of CER-1236 in ovarian cancer SOUTH SAN FRANSCISCO, Calif., March 05, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (Nasdaq: CERO) (“CERo” or the “Company”) an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, announces it will be presenting preclinical results of lead compound CER-1236 in ovarian cancer during the Spring Scientific from the Society for Immunotherapy of Cancer (SITC) in San Diego, March 12-14.
CERo Therapeutics Announces $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules
SOUTH SAN FRANSCISCO, Calif., Feb. 05, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (Nasdaq: CERO) (“CERo” or the “Company”) an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, today announced the pricing of its “reasonable best efforts” public offering with participation from a member of the Company's board and a single institutional investor for the purchase and sale of 2,551,020 shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to 2,551,020 shares of common stock at a combined purchase price of $1.96 (the “Offering”). The warrants will have an exercise price of $1.96 per share, will be immediately exercisable upon stockholder approval and will expire 5 years from the initial exercise date.
CERo Therapeutics, Inc. Appoints Chris Ehrlich CEO
SOUTH SAN FRANCISCO, Calif, Dec. 06, 2024 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (Nasdaq: CERO) (“CERo”), an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics augmented with phagocytic mechanisms derived from the innate arm of the immune system, announces its Board of Directors has appointed Chris Ehrlich as CEO. Previously he held the position of Interim CEO.
CERo Therapeutics, Inc. Receives FDA Clearance of Investigational New Drug Application to Initiate Phase 1 Clinical Trial of Its Lead Compound CER-1236 in Acute Myelogenous Leukemia
SOUTH SAN FRANCISCO, Calif, Nov. 15, 2024 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (Nasdaq: CERO) (“CERo”), an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics augmented with phagocytic mechanisms derived from the innate arm of the immune system, announces that the U.S. Food and Drug Administration (FDA) has cleared the Company's Investigational New Drug Application (IND) for Phase 1 clinical trials of its lead compound, CER-1236, in acute myelogenous leukemia (AML).
CERo Therapeutics, Inc. Presents Preclinical Data Demonstrating CER-1236 Killing Ovarian Cancer Cell Lines Without Toxicity
Data presented as part of a poster at the SITC 2024 Conference SOUTH SAN FRANCISCO, Calif., Nov. 11, 2024 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (Nasdaq: CERO) (“CERo”), an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, announces the presentation of preclinical data demonstrating the capability of its lead compound CER-1236 to kill ovarian cancer cells in preclinical models with no indications of toxicity in animal models.
CERo Therapeutics, Inc. Provides Corporate Update
Company announces submission of IND Clinical Hold Complete Response Letter SOUTH SAN FRANCISCO, Calif., Oct. 21, 2024 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (Nasdaq: CERO) (“CERo”), an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, provides the following corporate update to stockholders from Interim CEO Chris Ehrlich.
CERo Therapeutics, Inc. Names Al Kucharchuk Chief Financial Officer and Kristen Pierce Chief Development Officer
SOUTH SAN FRANCISCO, Calif, Oct. 02, 2024 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (Nasdaq: CERO) (“CERo”), an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, announces key appointments to the Company's management team to support recently named interim CEO, Chris Ehrlich. Andrew Albert “Al” Kucharchuk has been named Chief Financial Officer and Kristen Pierce, Ph.D., has been appointed Chief Development Officer.
CERo Therapeutics, Inc. Completes IND-Enabling Activities Following Successful Manufacturing Runs for Lead Compound CER-1236
Company anticipates near term filing of Investigational New Drug Application to FDA SOUTH SAN FRANCISCO, Calif., June 13, 2024 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (Nasdaq: CERO) (“CERo”), an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, announced it successfully executed pre-IND manufacturing activities for its lead therapeutic, CER-1236.
CERo Therapeutics, Inc. Provides Corporate Update for Shareholders
SOUTH SAN FRANCISCO, Calif., May 15, 2024 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (Nasdaq:CERO) (“CERo”) an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, provides shareholders with a corporate update reviewing activities since its entering the public market.
CERo Therapeutics Holdings Earnings
This section highlights CERo Therapeutics Holdings's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|
Financial Statements
Access annual & quarterly financial statements for CERo Therapeutics Holdings, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | December 31, 2023 | December 31, 2022 | December 31, 2021 |
|---|---|---|---|
| Revenue | $- | $- | $- |
| Cost of Revenue | $- | $- | $- |
| Gross Profit | $- | $- | $- |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% |
| Research and Development Expenses | $- | $9.85M | $9.14M |
| General and Administrative Expenses | $2.89K | $2.13M | $2.48M |
| Selling and Marketing Expenses | $2.89M | $715.76K | $-2.23M |
| Selling General and Administrative Expenses | $2.89M | $2.84M | $251.71K |
| Other Expenses | $40.05K | $-64.05K | $-80.32K |
| Operating Expenses | $2.93M | $2.91M | $332.03K |
| Cost and Expenses | $2.93M | $2.91M | $332.03K |
| Interest Income | $491.57K | $142.12K | $986.71K |
| Interest Expense | $- | $- | $- |
| Depreciation and Amortization | $2.93K | $1.07M | $735.47K |
| EBITDA | $-2.44M | $-68.58K | $-332.03K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% |
| Operating Income | $-2.93M | $-2.91M | $-332.03K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% |
| Total Other Income Expenses Net | $491.57K | $2.84M | $99.08K |
| Income Before Tax | $-2.44M | $-68.58K | $-332.42K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | $94.82K | $599.16K | $-16.87K |
| Net Income | $-2.54K | $-667.74K | $-315.55K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% |
| EPS | $-0.39 | $-0.10 | $-0.01 |
| EPS Diluted | $-0.39 | $-0.10 | $-0.01 |
| Weighted Average Shares Outstanding | 6.53M | 6.77M | 22.98M |
| Weighted Average Shares Outstanding Diluted | 6.53M | 6.77M | 22.98M |
| SEC Filing | Source | Source | Source |
Income Statement Charts
| Breakdown | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | June 30, 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Cost of Revenue | $- | $293.25K | $288.16K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Gross Profit | $- | $-293.25K | $-288.16K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research and Development Expenses | $1.77M | $2.71M | $1.38M | $- | $- | $1.19M | $1.80M | $- | $- | $- | $- | $- | $- |
| General and Administrative Expenses | $2.63M | $2.43M | $2.88M | $374.59K | $430.90K | $1.22M | $638.35K | $1.37M | $786.68K | $- | $- | $- | $1.00K |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- | $300.22K | $-71.78K | $- | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $2.63M | $2.43M | $2.88M | $374.59K | $430.90K | $1.52M | $566.57K | $1.37M | $786.68K | $326.58K | $354.78K | $251.71K | $1.00K |
| Other Expenses | $- | $- | $- | $5.25K | $1.10K | $-22.70K | $-23.70K | $85.95K | $-50.00K | $-50.00K | $-50.00K | $-80.32K | $- |
| Operating Expenses | $4.40M | $5.15M | $4.26M | $369.34K | $429.80K | $1.54M | $590.27K | $1.29M | $836.68K | $376.58K | $404.78K | $332.03K | $1.00K |
| Cost and Expenses | $4.40M | $5.15M | $4.55M | $369.34K | $429.80K | $1.54M | $590.27K | $1.29M | $836.68K | $376.58K | $404.78K | $332.03K | $1.00K |
| Interest Income | $4.42K | $- | $- | $110.99K | $121.52K | $59.42K | $16 | $2.48M | $320.48K | $37.11K | $17.27K | $- | $- |
| Interest Expense | $- | $16.98K | $9.63K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Depreciation and Amortization | $- | $293.25K | $288.16K | $369.34K | $429.80K | $277.45K | $273.58K | $1.29M | $836.68K | $- | $- | $- | $1.00K |
| EBITDA | $-4.40M | $-2.14M | $-2.00M | $- | $-429.80K | $-2.30M | $-2.32M | $- | $- | $-376.58K | $-404.78K | $-332.03K | $- |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | $-4.40M | $-5.15M | $-4.55M | $-369.34K | $-429.80K | $-1.54M | $-590.27K | $-1.29M | $-836.68K | $-376.58K | $-404.78K | $-332.03K | $-1.00K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income Expenses Net | $174.27K | $2.70M | $2.25M | $110.99K | $121.52K | $321.24K | $16 | $1.56M | $981.65K | $265.01K | $26.78K | $99.08K | $- |
| Income Before Tax | $-4.23M | $-2.45M | $-2.30M | $-258.35K | $-308.28K | $-1.39M | $-481.71K | $276.02K | $144.97K | $-111.57K | $-378.00K | $-331.42K | $-1.00K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | $- | $- | $-1 | $24.41K | $25.75K | $44.66K | $-273.58K | $538.70K | $60.46K | $- | $- | $-16.87K | $- |
| Net Income | $-4.23M | $-2.45M | $-2.30M | $-282.76K | $-334.03K | $-1.42M | $-481.71K | $-262.68K | $84.50K | $-111.57K | $-378.00K | $-314.55K | $-1.00K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | $-0.09 | $-0.15 | $-0.16 | $-0.05 | $-0.05 | $-0.21 | $-0.07 | $-0.04 | $0.00 | $0.00 | $-0.02 | $-0.01 | $0.00 |
| EPS Diluted | $-0.09 | $-0.15 | $-0.16 | $-0.05 | $-0.05 | $-0.21 | $-0.07 | $-0.04 | $0.00 | $0.00 | $-0.02 | $-0.01 | $0.00 |
| Weighted Average Shares Outstanding | 49.68M | 16.20M | 14.71M | 6.25M | 6.33M | 6.77M | 6.77M | 6.77M | 22.98M | 22.98M | 22.98M | 22.98M | 4.69M |
| Weighted Average Shares Outstanding Diluted | 49.68M | 16.20M | 14.71M | 6.25M | 6.33M | 6.77M | 6.77M | 6.77M | 22.98M | 22.98M | 22.98M | 22.98M | 4.68M |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | December 31, 2023 | December 31, 2022 | December 31, 2021 |
|---|---|---|---|
| Cash and Cash Equivalents | $96.87K | $42.14M | $1.10M |
| Short Term Investments | $8.44M | $- | $- |
| Cash and Short Term Investments | $96.87K | $42.14M | $1.10M |
| Net Receivables | $- | $- | $- |
| Inventory | $- | $- | $- |
| Other Current Assets | $8.46M | $225.19K | $262.50K |
| Total Current Assets | $8.56M | $42.37M | $1.36M |
| Property Plant Equipment Net | $- | $4.27M | $4.65M |
| Goodwill | $- | $- | $- |
| Intangible Assets | $- | $- | $- |
| Goodwill and Intangible Assets | $- | $- | $-4.65M |
| Long Term Investments | $- | $- | $178.50M |
| Tax Assets | $- | $- | $16.87K |
| Other Non-Current Assets | $- | $- | $200.65K |
| Total Non-Current Assets | $- | $4.27M | $178.72M |
| Other Assets | $- | $-4.27M | $- |
| Total Assets | $8.56M | $42.37M | $180.08M |
| Account Payables | $3.54M | $391.19K | $14.43K |
| Short Term Debt | $1.55M | $650.00K | $- |
| Tax Payables | $23.63K | $599.16K | $- |
| Deferred Revenue | $- | $207.97K | $-1.05M |
| Other Current Liabilities | $59.70K | $29.11M | $83.64K |
| Total Current Liabilities | $5.17M | $30.75M | $98.07K |
| Long Term Debt | $- | $2.34M | $3.02M |
| Deferred Revenue Non-Current | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- |
| Other Non-Current Liabilities | $17.59M | $6.81M | $6.13M |
| Total Non-Current Liabilities | $17.59M | $9.15M | $9.15M |
| Other Liabilities | $- | $- | $- |
| Total Liabilities | $22.76M | $39.90M | $9.25M |
| Preferred Stock | $- | $- | $- |
| Common Stock | $547 | $13.22M | $178.50M |
| Retained Earnings | $-14.20M | $-10.76M | $-7.67M |
| Accumulated Other Comprehensive Income Loss | $0 | $- | $- |
| Other Total Stockholders Equity | $-0 | $- | $- |
| Total Stockholders Equity | $-14.20M | $2.47M | $170.83M |
| Total Equity | $-14.20M | $2.47M | $170.83M |
| Total Liabilities and Stockholders Equity | $8.56M | $42.37M | $180.08M |
| Minority Interest | $- | $- | $- |
| Total Liabilities and Total Equity | $8.56M | $42.37M | $180.08M |
| Total Investments | $8.44M | $- | $178.50M |
| Total Debt | $1.55M | $650.00K | $3.60M |
| Net Debt | $1.46M | $-41.49M | $2.50M |
Balance Sheet Charts
| Breakdown | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $3.38M | $3.65M | $4.59M | $96.87K | $119.01K | $105.23K | $178.09K | $42.14M | $507.92K | $553.77K | $790.48K | $1.10M | $- | $- |
| Short Term Investments | $- | $- | $- | $8.44M | $8.33M | $13.90M | $- | $- | $- | $- | $- | $- | $- | $- |
| Cash and Short Term Investments | $3.38M | $3.65M | $4.59M | $8.53M | $8.45M | $14.00M | $178.09K | $42.14M | $507.92K | $553.77K | $790.48K | $1.10M | $- | $- |
| Net Receivables | $- | $87.43K | $162.06K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Inventory | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Current Assets | $334.28K | $511.46K | $746.04K | $8.46M | $8.35M | $14.01M | $220.29K | $450.38K | $277.38K | $292.25K | $307.12K | $525.00K | $24.00K | $24.00K |
| Total Current Assets | $3.71M | $4.25M | $5.50M | $8.56M | $8.47M | $14.11M | $398.39K | $42.37M | $785.29K | $846.02K | $1.10M | $1.36M | $24.00K | $24.00K |
| Property Plant Equipment Net | $2.28M | $2.57M | $2.87M | $- | $- | $- | $4.00M | $- | $- | $- | $- | $- | $- | $- |
| Goodwill | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Intangible Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Long Term Investments | $- | $- | $2.50M | $- | $- | $- | $14.03M | $- | $179.64M | $178.79M | $178.53M | $178.50M | $- | $- |
| Tax Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $16.87K | $- | $- |
| Other Non-Current Assets | $500.00K | $550.00K | $683.35K | $- | $- | $- | $-4.00M | $- | $21.18K | $87.35K | $152.79K | $200.65K | $277.00K | $1.00K |
| Total Non-Current Assets | $2.78M | $3.12M | $6.05M | $- | $- | $- | $14.03M | $- | $179.67M | $178.88M | $178.68M | $178.72M | $277.00K | $1.00K |
| Other Assets | $- | $- | $- | $- | $- | $- | $1 | $- | $- | $- | $1 | $- | $1 | $- |
| Total Assets | $6.49M | $7.37M | $11.55M | $8.56M | $8.47M | $14.11M | $14.43M | $42.37M | $180.45M | $179.72M | $179.78M | $180.08M | $301.00K | $25.00K |
| Account Payables | $6.67M | $6.35M | $7.06M | $3.54K | $3.31K | $3.15K | $868.86K | $1.65K | $710 | $- | $- | $- | $- | $1.00K |
| Short Term Debt | $1.03M | $1.07M | $1.20M | $5.05M | $4.65M | $4.19M | $650.00K | $650.00K | $- | $- | $- | $- | $- | $- |
| Tax Payables | $85.15K | $78.45K | $78.45K | $23.63K | $28.77K | $66.72K | $599.16K | $599.16K | $60.46K | $- | $- | $- | $- | $- |
| Deferred Revenue | $49.12K | $- | $-7.06K | $20.10K | $25.46K | $63.57K | $-269.70K | $597.50K | $- | $- | $- | $- | $- | $- |
| Other Current Liabilities | $1.64M | $1.28M | $3.32M | $3.57M | $3.35M | $3.10M | $1.18M | $29.50M | $814.80K | $234.21K | $174.66K | $98.07K | $277.00K | $- |
| Total Current Liabilities | $9.42M | $8.78M | $11.65M | $5.17M | $4.80M | $4.41M | $3.29M | $30.75M | $875.97K | $234.21K | $174.66K | $98.07K | $277.00K | $1.00K |
| Long Term Debt | $771.52K | $1.07M | $1.37M | $- | $- | $- | $2.16M | $- | $- | $- | $- | $- | $- | $- |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $- | $- | $13.72K | $9.15M | $9.15M | $9.15M | $6.99M | $9.15M | $9.15M | $9.15M | $9.15M | $9.15M | $- | $- |
| Total Non-Current Liabilities | $771.52K | $1.07M | $1.38M | $9.15M | $9.15M | $9.15M | $9.15M | $9.15M | $9.15M | $9.15M | $9.15M | $9.15M | $- | $- |
| Other Liabilities | $- | $- | $1 | $1 | $1 | $1 | $- | $- | $- | $1 | $- | $- | $- | $- |
| Total Liabilities | $10.19M | $9.85M | $13.03M | $14.32M | $13.95M | $13.56M | $12.44M | $39.90M | $10.03M | $9.38M | $9.32M | $9.25M | $277.00K | $1.00K |
| Preferred Stock | $1.25M | $9.44M | $9.44M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock | $14.75K | $2.27K | $1.45K | $8.44M | $8.29M | $13.84M | $13.57M | $13.22M | $179.48M | $178.50M | $178.50M | $178.50M | $467 | $468 |
| Retained Earnings | $-71.59M | $-67.36M | $-64.91M | $-14.20M | $-13.77M | $-13.29M | $-11.58M | $-10.76M | $-9.06M | $-8.16M | $-8.05M | $-7.67M | $-1.00K | $-1.00K |
| Accumulated Other Comprehensive Income Loss | $- | $-8.94M | $-2.50K | $0 | $- | $- | $0 | $- | $- | $- | $- | $- | $- | $-0 |
| Other Total Stockholders Equity | $66.62M | $73.32M | $56.49M | $-0 | $-1 | $- | $- | $- | $- | $- | $- | $- | $24.53K | $24.53K |
| Total Stockholders Equity | $-3.70M | $-2.48M | $-1.48M | $-5.76M | $-5.48M | $549.25K | $1.99M | $2.47M | $170.43M | $170.34M | $170.45M | $170.83M | $24.00K | $24.00K |
| Total Equity | $-3.70M | $-2.48M | $-1.48M | $-5.76M | $-5.48M | $549.25K | $1.99M | $2.47M | $170.43M | $170.34M | $170.45M | $170.83M | $24.00K | $24.00K |
| Total Liabilities and Stockholders Equity | $6.49M | $7.37M | $11.55M | $8.56M | $8.47M | $14.11M | $14.43M | $42.37M | $180.45M | $179.72M | $179.78M | $180.08M | $301.00K | $25.00K |
| Minority Interest | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $6.49M | $7.37M | $11.55M | $8.56M | $8.47M | $14.11M | $14.43M | $42.37M | $180.45M | $179.72M | $179.78M | $180.08M | $301.00K | $25.00K |
| Total Investments | $- | $2.19M | $2.50M | $8.44M | $8.33M | $13.90M | $14.03M | $- | $179.64M | $178.79M | $178.53M | $178.50M | $- | $- |
| Total Debt | $1.80M | $2.15M | $2.56M | $1.55M | $1.40M | $1.18M | $650.00K | $650.00K | $- | $- | $- | $- | $- | $- |
| Net Debt | $-1.58M | $-1.50M | $-2.03M | $1.46M | $1.28M | $1.07M | $471.91K | $-41.49M | $-507.92K | $-553.77K | $-790.48K | $-1.10M | $- | $- |
Annual Cash Flow
| Breakdown | December 31, 2023 | December 31, 2022 | December 31, 2021 |
|---|---|---|---|
| Net Income | $-2.54K | $-667.74K | $-315.55K |
| Depreciation and Amortization | $- | $1.07M | $735.47K |
| Deferred Income Tax | $- | $- | $- |
| Stock Based Compensation | $- | $381.07K | $287.74K |
| Change in Working Capital | $198 | $2.41M | $-365.08K |
| Accounts Receivables | $- | $- | $- |
| Inventory | $- | $- | $- |
| Accounts Payables | $- | $-68.73K | $212.17K |
| Other Working Capital | $198 | $2.41M | $-365.08K |
| Other Non Cash Items | $815 | $-2.84M | $-16.48K |
| Net Cash Provided by Operating Activities | $-1.52K | $-1.09M | $-697.11K |
| Investments in Property Plant and Equipment | $- | $-694.23K | $-612.57K |
| Acquisitions Net | $- | $- | $- |
| Purchases of Investments | $-14.34M | $-325.00K | $-178.50M |
| Sales Maturities of Investments | $5.64M | $- | $- |
| Other Investing Activities | $8.69M | $181.16M | $-306.00K |
| Net Cash Used for Investing Activities | $-7.94K | $180.84M | $-178.50M |
| Debt Repayment | $905.00K | $650.00K | $- |
| Common Stock Issued | $- | $- | $180.30M |
| Common Stock Repurchased | $-33.48K | $-139.35M | $- |
| Dividends Paid | $- | $- | $- |
| Other Financing Activities | $-904.10K | $-139.21M | $60.26K |
| Net Cash Used Provided by Financing Activities | $-32.58K | $-138.70M | $180.30M |
| Effect of Forex Changes on Cash | $- | $- | $- |
| Net Change in Cash | $-42.04K | $41.04M | $-28.77M |
| Cash at End of Period | $97 | $42.14M | $1.10M |
| Cash at Beginning of Period | $42.14K | $1.10M | $29.86M |
| Operating Cash Flow | $-1.52K | $-1.09M | $-697.11K |
| Capital Expenditure | $4 | $-694.23K | $-612.57K |
| Free Cash Flow | $-1.52K | $-1.79M | $-1.31M |
Cash Flow Charts
| Breakdown | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | June 30, 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $-1.49M | $-2.45M | $-2.30M | $-282.76K | $-334.03K | $-2.09M | $-2.44M | $-262.68K | $84.50K | $-111.57K | $-378.00K | $-314.55K | $-1 |
| Depreciation and Amortization | $281.41K | $293.25K | $288.16K | $- | $- | $277.45K | $273.58K | $- | $- | $- | $- | $- | $- |
| Deferred Income Tax | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Stock Based Compensation | $23.50K | $1.40M | $100.72K | $- | $- | $27.28K | $28.14K | $- | $- | $- | $- | $- | $- |
| Change in Working Capital | $-627.76K | $841.41K | $-905.37K | $207.14K | $199.43K | $-35.50K | $663.27K | $1.45M | $722.80K | $139.87K | $96.69K | $-366.08K | $- |
| Accounts Receivables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Inventory | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Accounts Payables | $205.90K | $- | $-286.49K | $- | $- | $209.19K | $477.68K | $- | $- | $- | $- | $- | $- |
| Other Working Capital | $-833.66K | $841.41K | $-618.88K | $207.14K | $199.43K | $108.78K | $185.59K | $1.45M | $662.34K | $139.87K | $96.69K | $-366.08K | $- |
| Other Non Cash Items | $498.11K | $-3.62M | $-1.30M | $-110.99K | $-121.52K | $445.86K | $514.33K | $-1.56M | $-981.65K | $-265.01K | $-26.78K | $-16.48K | $1 |
| Net Cash Provided by Operating Activities | $-1.32M | $-3.54M | $-5.08M | $-186.61K | $-256.12K | $-2.07M | $-1.44M | $-373.10K | $-174.35K | $-236.71K | $-308.09K | $-697.11K | $- |
| Investments in Property Plant and Equipment | $- | $4 | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Acquisitions Net | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Purchases of Investments | $- | $- | $- | $-13.89M | $-68.85K | $- | $- | $-325.00K | $- | $- | $- | $-178.50M | $- |
| Sales Maturities of Investments | $- | $- | $- | $- | $5.08M | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Investing Activities | $- | $- | $- | $73.31K | $678.99K | $285.24K | $- | $181.04M | $128.49K | $- | $- | $- | $- |
| Net Cash Used for Investing Activities | $- | $- | $- | $-13.82M | $5.69M | $285.24K | $- | $180.71M | $128.49K | $- | $- | $-178.50M | $- |
| Debt Repayment | $- | $- | $-19.71K | $- | $- | $605.23K | $- | $- | $- | $- | $- | $- | $- |
| Common Stock Issued | $- | $2.74M | $6.76M | $- | $- | $- | $- | $- | $- | $- | $- | $180.30M | $- |
| Common Stock Repurchased | $- | $- | $- | $-27.84M | $-5.64M | $- | $- | $-139.35M | $- | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Financing Activities | $-1 | $2.59M | $7.18M | $160.00K | $220.00K | $-38.72K | $5.17K | $650.88K | $- | $- | $- | $180.30M | $- |
| Net Cash Used Provided by Financing Activities | $-1 | $2.59M | $7.16M | $-27.68M | $-5.42M | $566.51K | $5.17K | $-138.70M | $- | $- | $- | $180.30M | $- |
| Effect of Forex Changes on Cash | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Net Change in Cash | $-1.32M | $-946.08K | $4.50M | $-22.14K | $13.78K | $-1.51M | $-1.43M | $41.63M | $-45.86K | $-236.71K | $-308.09K | $1.10M | $- |
| Cash at End of Period | $2.56M | $4.61M | $4.59M | $96.87K | $119.01K | $3.88M | $5.39M | $42.14M | $507.92K | $553.77K | $790.48K | $1.10M | $- |
| Cash at Beginning of Period | $3.88M | $5.56M | $96.87K | $119.01K | $105.23K | $5.39M | $6.82M | $507.92K | $553.77K | $790.48K | $1.10M | $- | $- |
| Operating Cash Flow | $-1.32M | $-3.54M | $-5.08M | $-186.61K | $-256.12K | $-2.07M | $-1.44M | $-373.10K | $-174.35K | $-236.71K | $-308.09K | $-697.11K | $- |
| Capital Expenditure | $- | $4 | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Free Cash Flow | $-1.32M | $-3.54M | $-5.08M | $-186.61K | $-256.12K | $-2.07M | $-1.44M | $-373.10K | $-174.35K | $-236.71K | $-308.09K | $-697.11K | $- |
CERo Therapeutics Holdings Dividends
Explore CERo Therapeutics Holdings's dividend history, including dividend yield, payout ratio, and historical payments.
Peers: Biotechnology
This section provides companies within the same sector, on the same exchange, and of similar market capitalization, allowing comparisons of key financial indicators among peers.
| Company | Market Cap | Price | EPS | P/E Ratio | P/B Ratio |
|---|
Related Metrics
Explore detailed financial metrics and analysis for CERO.